-
A Message from the Editor-in-Chief: End of An Era
A final goodbye It is with a heavy heart that I write this last piece for Perspectives in Primary Care. Current financial realities have necessitated... -
An Underrated Barrier to Healthcare: It's Not Just About Cost
“Thank you for calling our free clinic. How can I help you?” I have spent countless hours listening to the pleas of people in desperate need of... -
A Guide to Geriatric Psychiatry Referral for Health Care Professionals and Caregivers
Our aging global population has the potential to enrich our communities, strengthen intergenerational relationships, and help preserve our cultural...
Archive
As of June 30, 2025, Perspectives in Primary Care is no longer active.
Perspectives in Primary Care features writing from practitioners, activists, and community members representing organizations, practices, and institutions across the United States and around the world.
Reference
The New Landscape of Obesity Medicine: What Does This Mean for Patients?
With the development and expanded use of medications for the treatment of obesity, we are able to broaden the tools we can offer patients to treat this condition. Medications like Wegovy and Ozempic have become household names. These medications are classified as glucagon-like peptide-1 (GLP-1) receptor agonists. Glucagon-like peptides are hormones that are naturally produced in the gut (intestines) that help regulate blood sugars and hunger signaling. Since these natural hormones last in our bodies for only a few minutes, GLP-1 medications create longer lasting signaling to potentiate ...
